EMA Upholds Negative Opinion on Omeros’ Narsoplimab Application
The EMA committee upheld its negative opinion on Omeros’ marketing authorization application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy.
Kelly CloonanA committee from the European Medicines Agency upheld its negative opinion on Omeros' marketing authorization application for narsoplimab, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.The EMA's Committee for Medicinal Products for Human Use h…